HUP0103887A2 - N-aralkilaminotetralinok neuropeptid Y Y5 receptor ligandumként és ilyen vegyületeket hatóanyagként tartalmazó gyógyszerkészítmények - Google Patents
N-aralkilaminotetralinok neuropeptid Y Y5 receptor ligandumként és ilyen vegyületeket hatóanyagként tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0103887A2 HUP0103887A2 HU0103887A HUP0103887A HUP0103887A2 HU P0103887 A2 HUP0103887 A2 HU P0103887A2 HU 0103887 A HU0103887 A HU 0103887A HU P0103887 A HUP0103887 A HU P0103887A HU P0103887 A2 HUP0103887 A2 HU P0103887A2
- Authority
- HU
- Hungary
- Prior art keywords
- optionally substituted
- alkyl
- compounds
- cycloalkyl
- alkylene
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 101710151321 Melanostatin Proteins 0.000 title 1
- 102400000064 Neuropeptide Y Human genes 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 nitro- Chemical class 0.000 abstract 9
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000004419 alkynylene group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Indole Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
A találmány tárgya (I) általános képletű vegyületek, ezekenantiomerjei, diasztereomerjei és gyógyszerészetileg elfogadható sói- a képletben R1 jelentése egymástól függetlenül hidrogénatom,hidroxi-, halogén-, 1-4 szénatomos alkil-; adott esetben szubsztituált1-4 szénatomos alkoxi-; trifluoralkil-; adott esetben szubsztituált 1-8 szénatomos alkiltio-, 3-6 szénatomos cikloalkil-; 3-8 szénatomoscikloalkiloxi-; nitro-; amino-; 1-6 szénatomos alkilamino-; 1-8szénatomos dialkilamino-; 4-8 szénatomos cikloalkilamino-; ciano-;karboxi-; 1-5 szénatomos alkoxikarbonil-; 1-5 szénatomosalkilkarboniloxi-; formil-; karbamoil-; adott esetben szubsztituáltfenilcsoport; n értéke 0-2, R2 jelentése hidrogénatom; 1-6 szénatomosalkil-; 2-6 szénatomos alkenil-; halogén-, így fluor- vagy klóratom;3-7 szénatomos cikloalkil-; adott esetben szubsztituált fenil-;naftil-; adott esetben szubsztituált fenoxi-; adott esetbenszubsztituált feniltio-; adott esetben szubsztituáltheteroarilcsoport; L jelentése 1-8 szénatomos alkilén-; 2-8 szénatomosalkenilén-; 2-8 szénatomos alkinilén-; 1-4 szénatomos alkilén-3-8szénatomos cikloalkiléncsoport; R3 jelentése 1-8 szénatomos alkil-;adott esetben szubsztituált 1-8 szénatomos alkil-; alkoxialkiloxi-;adott esetben szubsztituált cikloalkil-; adott esetben szubsztituáltfenil-; adott esetben szubsztituált naftil-; adott esetbenszubsztituált heteroarilcsoport; A találmány vonatkozik továbbá afenti (I) általános képletű vegyületeket hatóanyagként tartalmazógyógyszerkészítményekre is. Ó
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10344698P | 1998-10-07 | 1998-10-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0103887A2 true HUP0103887A2 (hu) | 2002-05-29 |
HUP0103887A3 HUP0103887A3 (en) | 2002-06-28 |
Family
ID=22295225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0103887A HUP0103887A3 (en) | 1998-10-07 | 1999-10-06 | N-aralkylaminotetralins as ligands for the neuropeptide y y5 receptor and pharmaceutical compositions containing such compounds |
Country Status (16)
Country | Link |
---|---|
US (1) | US6201025B1 (hu) |
EP (1) | EP1119543B1 (hu) |
JP (1) | JP2002526521A (hu) |
CN (1) | CN1329589A (hu) |
AT (1) | ATE284861T1 (hu) |
AU (1) | AU763886B2 (hu) |
BR (1) | BR9914360A (hu) |
CA (1) | CA2346363A1 (hu) |
DE (1) | DE69922676T2 (hu) |
ES (1) | ES2235521T3 (hu) |
HU (1) | HUP0103887A3 (hu) |
NO (1) | NO20011721L (hu) |
NZ (1) | NZ510988A (hu) |
PT (1) | PT1119543E (hu) |
TW (1) | TW593226B (hu) |
WO (1) | WO2000020376A1 (hu) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2373035A1 (en) * | 1999-05-05 | 2000-11-16 | Scott Dax | 3a,4,5,9b-tetrahydro-1h-benz[e]indol-2-yl amine-derived neuropeptide y receptors ligands useful in the treatment of obesity and other disorders |
US6841552B1 (en) | 1999-05-05 | 2005-01-11 | Ortho-Mcneil Pharmaceutical, Inc. | 3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptide Y receptors ligands useful in the treatment of obesity and other disorders |
JP2003506367A (ja) * | 1999-07-28 | 2003-02-18 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 肥満症および他の障害の処置に有用な神経ペプチドyy5レセプターのリガンドとしてのアミンおよびアミド誘導体 |
GB0010757D0 (en) | 2000-05-05 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
GB0121941D0 (en) | 2001-09-11 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
DE60230818D1 (de) * | 2001-09-24 | 2009-02-26 | Imp Innovations Ltd | Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit |
US8058233B2 (en) * | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
ES2193875B2 (es) | 2002-04-09 | 2005-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos. |
JP2005526137A (ja) * | 2002-05-17 | 2005-09-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | アミノテトラリン−誘動尿素のバニロイドvr1受容体調節剤 |
GB0300571D0 (en) * | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
ES2222833B1 (es) | 2003-07-30 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos. |
WO2005114211A1 (en) * | 2004-05-21 | 2005-12-01 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor nyp5 (npy5) |
WO2006108218A1 (en) * | 2005-04-15 | 2006-10-19 | Regenertech Pty Limited | Use of neuropeptide y (npy) and agonists and antagonists thereof for tissue regeneration |
GB0511986D0 (en) * | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
TWI428346B (zh) * | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
US8653100B2 (en) | 2008-04-01 | 2014-02-18 | Abbvie Inc. | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy |
AR075442A1 (es) | 2009-02-16 | 2011-03-30 | Abbott Gmbh & Co Kg | Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia |
US9051280B2 (en) | 2010-08-13 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8877794B2 (en) | 2010-08-13 | 2014-11-04 | Abbott Laboratories | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8846743B2 (en) | 2010-08-13 | 2014-09-30 | Abbott Laboratories | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9045459B2 (en) | 2010-08-13 | 2015-06-02 | AbbVie Deutschland GmbH & Co. KG | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US8883839B2 (en) | 2010-08-13 | 2014-11-11 | Abbott Laboratories | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9309200B2 (en) | 2011-05-12 | 2016-04-12 | AbbVie Deutschland GmbH & Co. KG | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy |
JP2014521682A (ja) | 2011-08-05 | 2014-08-28 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | アミノクロマン、アミノチオクロマンおよびアミノ−1,2,3,4−テトラヒドロキノリン誘導体、これらを含有する医薬組成物、ならびに治療におけるこれらの使用 |
CN104011028A (zh) | 2011-11-18 | 2014-08-27 | 艾伯维德国有限责任两合公司 | N-取代的氨基苯并环庚烯、氨基四氢化萘、氨基茚满和苯烷基胺衍生物、包含所述衍生物的药物组合物及其在治疗中的用途 |
US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9227901B2 (en) | 2012-07-05 | 2016-01-05 | Abbvie Inc. | Process for preparing bicyclic amine derivatives |
TW201422590A (zh) | 2012-09-07 | 2014-06-16 | Abbvie Inc | 雜環核激素受體調節劑 |
EP2935284A4 (en) | 2012-12-21 | 2016-04-27 | Abbvie Inc | HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS |
US9656955B2 (en) | 2013-03-15 | 2017-05-23 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9650334B2 (en) | 2013-03-15 | 2017-05-16 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
EP3057958B1 (en) | 2013-10-17 | 2019-05-01 | AbbVie Deutschland GmbH & Co. KG | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
AU2014336153A1 (en) | 2013-10-17 | 2016-04-28 | AbbVie Deutschland GmbH & Co. KG | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
CA3216096A1 (en) | 2021-06-08 | 2022-12-15 | Entheogenix Biosciences, Inc. | Dimethoxyphenylalkylamine activators of serotonin receptors |
CA3221823A1 (en) | 2021-06-09 | 2022-12-15 | Glenn Short | Novel prodrugs and conjugates of dimethyltryptamine |
US11827580B2 (en) | 2021-12-27 | 2023-11-28 | ATAI Life Sciences AG | Aminotetraline activators of serotonin receptors |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL65501A (en) * | 1981-05-08 | 1986-04-29 | Astra Laekemedel Ab | 1-alkyl-2-aminotetralin derivatives,process for their preparation and pharmaceutical compositions containing them |
US5286747A (en) * | 1981-05-08 | 1994-02-15 | Per A. E. Carlsson | 1-alkyl-2-aminotetralin derivatives |
CA1331191C (en) * | 1988-03-25 | 1994-08-02 | Bengt Ronny Andersson | Therapeutically useful tetralin derivatives |
US5340838A (en) * | 1990-05-04 | 1994-08-23 | Eli Lilly And Company | Method of inhibiting gastric acid secretion with 2-phenylcyclopropylamines |
AU7692896A (en) | 1995-12-01 | 1997-06-27 | Novartis Ag | Quinazolin-2,4-diazirines as NPY receptor antagonist |
-
1999
- 1999-10-06 PT PT99950218T patent/PT1119543E/pt unknown
- 1999-10-06 DE DE69922676T patent/DE69922676T2/de not_active Expired - Fee Related
- 1999-10-06 JP JP2000574494A patent/JP2002526521A/ja active Pending
- 1999-10-06 WO PCT/US1999/023259 patent/WO2000020376A1/en active IP Right Grant
- 1999-10-06 AU AU62923/99A patent/AU763886B2/en not_active Ceased
- 1999-10-06 CN CN99814214A patent/CN1329589A/zh active Pending
- 1999-10-06 BR BR9914360-7A patent/BR9914360A/pt not_active Application Discontinuation
- 1999-10-06 US US09/413,292 patent/US6201025B1/en not_active Expired - Lifetime
- 1999-10-06 CA CA002346363A patent/CA2346363A1/en not_active Abandoned
- 1999-10-06 AT AT99950218T patent/ATE284861T1/de not_active IP Right Cessation
- 1999-10-06 EP EP99950218A patent/EP1119543B1/en not_active Expired - Lifetime
- 1999-10-06 NZ NZ510988A patent/NZ510988A/en unknown
- 1999-10-06 ES ES99950218T patent/ES2235521T3/es not_active Expired - Lifetime
- 1999-10-06 HU HU0103887A patent/HUP0103887A3/hu unknown
- 1999-11-03 TW TW088117463A patent/TW593226B/zh not_active IP Right Cessation
-
2001
- 2001-04-05 NO NO20011721A patent/NO20011721L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
HUP0103887A3 (en) | 2002-06-28 |
DE69922676T2 (de) | 2005-12-15 |
US6201025B1 (en) | 2001-03-13 |
BR9914360A (pt) | 2001-11-20 |
DE69922676D1 (de) | 2005-01-20 |
CN1329589A (zh) | 2002-01-02 |
JP2002526521A (ja) | 2002-08-20 |
NO20011721D0 (no) | 2001-04-05 |
WO2000020376A1 (en) | 2000-04-13 |
NO20011721L (no) | 2001-06-05 |
EP1119543A1 (en) | 2001-08-01 |
AU763886B2 (en) | 2003-07-31 |
CA2346363A1 (en) | 2000-04-13 |
ES2235521T3 (es) | 2005-07-01 |
AU6292399A (en) | 2000-04-26 |
ATE284861T1 (de) | 2005-01-15 |
PT1119543E (pt) | 2005-03-31 |
EP1119543B1 (en) | 2004-12-15 |
NZ510988A (en) | 2005-01-28 |
TW593226B (en) | 2004-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0103887A2 (hu) | N-aralkilaminotetralinok neuropeptid Y Y5 receptor ligandumként és ilyen vegyületeket hatóanyagként tartalmazó gyógyszerkészítmények | |
HUP0204246A2 (hu) | Új tiazolo[4,5-d]pirimidin-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0100280A2 (hu) | Pirrolo-, tieno-, furano- és pirazolo [3,4d] piridazonok, eljárás az előállításukra és ezeket tartalmazó gyógyászati készítmények | |
HUP0301690A2 (hu) | Szinergikus eljárások és készítmények rák kezelésére | |
HUP0004024A2 (hu) | Azabenzimidazolvázas vegyületek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0101999A2 (hu) | 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása | |
HUP0002112A2 (hu) | Helyettesített 3-ciano-kinolinok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények | |
HUP0303756A2 (hu) | 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények | |
HUP0203458A2 (hu) | Nociceptin ORL-1 receptor agonisták alkalmazása köhögés kezelésére és ezeket tartalmazó gyógyszerkészítmények | |
HUP0402336A2 (hu) | Tieno[2,3-d]pirimidin-2,4-dion-származékok, eljárás előállításukra, alkalmazásuk autoimmun betegségek modulálására és a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0002347A2 (hu) | Hidantoin-, oxazol- és pirrolszármazékok alkalmazása gyulladásos betegségek kezelésére alkalmazható gyógyszerkészítmények előállítására | |
HUP0102425A2 (hu) | Gyomorsav-elválasztást gátló imidazo-piridin-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0004333A2 (hu) | Új triazolo [4,5-d] pirimidin-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0301336A2 (hu) | Réztartalmú amin-oxidázok inhibitorai és alkalmazásuk gyógyszerkészítmények előállítására | |
HUP0302487A2 (hu) | Új mandulasavszármazékok és felhasználásuk trombin inhibitorokként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0001309A2 (hu) | 1-Fenil-4-benzil-piperazinok és a vegyületeket tartalmazó gyógyászati készítmények | |
NO20050666L (no) | 2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer | |
NO20062491L (no) | Benzoksazinderivter og deres anvendelse | |
HUP0401638A2 (hu) | Daganatellenes hatású tiofén- és tiazolszulfonamid származékok, valamint ezeket tartalmazó gyógyászati készítmények | |
AU2002239348A1 (en) | Pyrazolopyridine derivatives | |
HUP0203245A2 (hu) | Foszfodiészteráz VII-inhibitorként használható imidazopiridinszármazékok és ezeket tartalmazó gyógyszerkészítmények | |
HUP0401235A2 (hu) | 5-HT6 receptor affinitással rendelkező arilszulfonil-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények | |
HUP0400370A2 (hu) | Antibakteriális hatású oxazolidinonszármazékok, előállításukra szolgáló eljárás, azokat hatóanyagként tartalmazó gyógyászati készítmények, alkalmazásuk és intermedierek | |
SE0200919D0 (sv) | Chemical compounds | |
AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |